Professor Michael Weller, a leading Neuro-oncologist who currently serves as the Chairman of the Department of Neurology at the University Hospital in Zurich, Switzerland and as the National Coordinating Investigator for CNS Pharmaceuticals' potentially pivotal study of Berubicin, discusses the unmet need in glioblastoma multiforme (GBM), the current treatment landscape and the potential for Berubicin to provide a solution for this devasting disease.